NCT06152653View on ClinicalTrials.gov

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
AsthmaCOPD
Interventions
DRUG

n-acetylcystine (NAC)+ albuterol

NAC is a mucolytic drug and Albuterol is a bronchodilator.

DEVICE

AeroEclipse-VersaPAP System

The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.

Trial Locations (1)

94143

RECRUITING

UCSF Airway Clinical Research Center, San Francisco

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of California, San Francisco

OTHER